Albert Oriol

Institut Català d'Oncologia

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (10)

Verónica González-Calle

University Hospital of Salamanca

Adam Jacob Bryant

University of New South Wales

Felipe de Arriba de la Fuente

Profesor Asociado

Universidad de Murcia

David Siegel

Chief, Myeloma Division

UNITED STATES

Pawel Robak

Medical University of Lodz

José María Bellón Cano

Instituto de Investigación Sanitaria Gregorio Marañón

David Gallardo

Associate professor

Universitat Autònoma de Barcelona Facultat de Medicina

Jesus F. San Miguel

MJ Calasanz

Full Professor of Genetics

Universidad de Navarra

Enrique M. Ocio

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Albert Oriol

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (10)

Verónica González-Calle

Adam Jacob Bryant

Felipe de Arriba de la Fuente

David Siegel

Pawel Robak

José María Bellón Cano

David Gallardo

Jesus F. San Miguel

MJ Calasanz

Enrique M. Ocio

Make your next move.

Albert Oriol

Research Interests

Explore related searches

Contact this professor

Articles (20)

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

CD200 genotype is associated with clinical outcome of patients with multiple myeloma.

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Dose intensity and treatment duration of bortezomib in transplant‐ineligible newly diagnosed multiple myeloma

Collaborators (10)

Verónica González-Calle

Adam Jacob Bryant

Felipe de Arriba de la Fuente

David Siegel

Pawel Robak

José María Bellón Cano

David Gallardo

Jesus F. San Miguel

MJ Calasanz

Enrique M. Ocio

Make your next move.